Comparative Pharmacology
Head-to-head clinical analysis: FAVLYXA versus HERPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAVLYXA versus HERPLEX.
FAVLYXA vs HERPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
Inhibits viral DNA polymerase after phosphorylation to acyclovir triphosphate, leading to chain termination and inhibition of herpes simplex virus replication.
200 mg orally twice daily for 10 days.
Acyclovir 200 mg orally 5 times daily for 10 days for initial genital herpes; 400 mg orally twice daily for suppressive therapy; 5-10 mg/kg IV every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
2.5–3.3 hours in adults with normal renal function; prolonged to 10–20 hours in anuria (CrCl <10 mL/min); requires dose adjustment in renal impairment
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Renal: ~90% as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<2%)
Category C
Category C
Antiviral
Antiviral